Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for URGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -170.43M
March 31, 2026 -175.58M
December 31, 2025 -172.29M
September 30, 2025 -143.64M
June 30, 2025 -123.90M
March 31, 2025 -107.04M
December 31, 2024 -96.76M
September 30, 2024 -94.88M
June 30, 2024 -83.38M
March 31, 2024 -79.63M
December 31, 2023 -73.70M
September 30, 2023 -82.21M
June 30, 2023 -82.56M
March 31, 2023 -86.11M
December 31, 2022 -84.30M
September 30, 2022 -85.50M
June 30, 2022 -87.62M
Date Value
March 31, 2022 -83.53M
December 31, 2021 -86.94M
September 30, 2021 -88.45M
June 30, 2021 -96.24M
March 31, 2021 -101.04M
December 31, 2020 -109.28M
September 30, 2020 -112.51M
June 30, 2020 -99.19M
March 31, 2020 -90.14M
December 31, 2019 -72.44M
September 30, 2019 -55.78M
June 30, 2019 -51.46M
March 31, 2019 -44.55M
December 31, 2018 -36.24M
September 30, 2018 -32.66M
June 30, 2018 -20.97M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Xencor, Inc. -205.81M
MeiraGTx Holdings Plc 13.69M
Insmed, Inc. -778.92M
Ironwood Pharmaceuticals, Inc. 185.56M
Viking Therapeutics, Inc. -418.44M